USA flag logo/image

An Official Website of the United States Government

IGF::OT::IGF OTHER FUNCTIONS - NOVEL IMAGING AGENTS TO EXPAND THE CLINICAL…

Award Information

Agency:
Department of Health and Human Services
Branch:
N/A
Award ID:
Program Year/Program:
2012 / SBIR
Agency Tracking Number:
N43CO120058
Solicitation Year:
2012
Solicitation Topic Code:
NCI
Solicitation Number:
Small Business Information
ARKIVAL TECHNOLOGY CORPORATION
34 FRANKLIN STREET NASHUA, NH 99999-
View profile »
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No
 
Phase 1
Fiscal Year: 2012
Title: IGF::OT::IGF OTHER FUNCTIONS - NOVEL IMAGING AGENTS TO EXPAND THE CLINICAL TOOLKIT FOR CANCER DIAGNOSIS, STAGING, AND TREATMENT
Agency: HHS
Contract: N43CO120058
Award Amount: $249,724.00
 

Abstract:

This technology introduces a new non-invasive, biopsy-adjunct with a MNP platform for targeted tumor delivery. It employs closely sized magnetic nanoparticles (CS-MNP's) for determining their concentration and spatial distribution in tumor vasculatures asmeasured by magnetic resonance imaging (MRI). The relationship between CS-MNP size and Vibrating Sample Magnetometer (VSM) measurement follows from the physics of superparamagnetism (SP- theory). By correlating particle size and concentration within a tumor and its MRI response, the data can likely deliver tumor characterization without biopsy. This work characterizes CS-MNP's, animal testing and the quantification of the MRI imaging signals. Resulting data supports continued development of CS-MNP-products and new patents. It addresses the production of CS- MNP products for preclinical studies and business development for a very large market requiring more precise, higher margin products. These new products and services represent the future of MNP-based products for imaging and drug delivery. This technology has potential for a new biopsy-adjunct with CS-MNP's for targeted tumor delivery. Measurement of CS-MNP's in the tumor vasculature by MRI may become a major diagnostic tool and use for targeted therapeutics. It may provide for differentiating benign disease from malignancy, insightful surgical planning, and evaluation of chemotherapy and radiation treatment

Principal Investigator:

Ron Weiss
603-881-3322
RON@ARKIVAL.COM

Business Contact:

Ron Weiss
603-881-3322
RON@ARKIVAL.COM
Small Business Information at Submission:

ARKIVAL TECHNOLOGY CORPORATION
34 FRANKLIN STREET NASHUA, NH 99999-

EIN/Tax ID: 999999999
DUNS: N/A
Number of Employees: N/A
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No